Auna S.A. (AUNA)vsAstraZeneca PLC (AZN)
AUNA
Auna S.A.
$4.41
-2.00%
HEALTHCARE · Cap: $333.25M
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1237% more annual revenue ($60.44B vs $4.52B). AZN leads profitability with a 17.2% profit margin vs 1.5%. AUNA trades at a lower P/E of 16.7x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AUNA
Hold49
out of 100
Grade: D+
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUNA.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.9% — below average capital efficiency
1.5% margin — thin
Weak financial health signals
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AUNA
The strongest argument for AUNA centers on Price/Book, P/E Ratio. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.19 is elevated, increasing financial risk. Thin 1.5% margins leave little buffer for downturns.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AUNA profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AUNA carries more volatility with a beta of 1.03 — expect wider price swings.
AUNA is growing revenue faster at 13.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 49/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a leading telecommunications and digital services provider in Latin America, offering a diverse range of integrated solutions that enhance connectivity for both residential and business clients. The company's extensive portfolio includes high-speed internet, television, and mobile services, underscoring its commitment to innovation and superior customer experience. Auna's robust infrastructure and strategic positioning enable it to capitalize on the increasing demand for advanced telecommunications solutions, making it an attractive investment opportunity for institutional investors seeking exposure to the region's expanding digital economy.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?